MTNB
AMEX · Biotechnology
Matinas Biopharma Holdings I
$0.57
+0.01 (+1.41%)
Financial Highlights (FY 2025)
Revenue
545.4K
Net Income
-151,735
Gross Margin
48.2%
Profit Margin
-27.8%
Rev Growth
-0.1%
D/E Ratio
0.35
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 48.2% | 48.2% | 48.2% |
| Operating Margin | -23.8% | -26.0% | -28.9% |
| Profit Margin | -27.8% | -25.0% | -32.4% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 545.4K | 506.2K | 440.2K |
| Gross Profit | 263.1K | 244.2K | 212.3K |
| Operating Income | -129,952 | -131,815 | -127,302 |
| Net Income | -151,735 | -126,413 | -142,621 |
| Gross Margin | 48.2% | 48.2% | 48.2% |
| Operating Margin | -23.8% | -26.0% | -28.9% |
| Profit Margin | -27.8% | -25.0% | -32.4% |
| Rev Growth | -0.1% | +13.2% | +21.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 999.5K | 1.14M | 980.1K |
| Total Equity | 2.84M | 3.26M | 3.09M |
| D/E Ratio | 0.35 | 0.35 | 0.32 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -193,711 | -167,268 | -163,365 |
| Free Cash Flow | -191,504 | -185,587 | -103,932 |